Login / Signup
Enliang Li
ORCID
Publication Activity (10 Years)
Years Active: 2023-2023
Publications (10 Years): 4
Top Topics
Combination Therapy
Poor Prognosis
Prognostic Factors
Ejection Fraction
Top Venues
Immunotherapy
</>
This page only lists publications with an associated author ORCID identifier.
Publications
</>
Enliang Li
,
Jian Xu
,
Qi Chen
,
Xiaozhen Zhang
,
Xingyuan Xu
,
Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
15 (3) (2023)
Enliang Li
,
Jian Xu
,
Qi Chen
,
Xiaozhen Zhang
,
Xingyuan Xu
,
Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
15 (3) (2023)
Enliang Li
,
Jian Xu
,
Qi Chen
,
Xiaozhen Zhang
,
Xingyuan Xu
,
Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
(2023)
Enliang Li
,
Jian Xu
,
Qi Chen
,
Xiaozhen Zhang
,
Xingyuan Xu
,
Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer.
Immunotherapy
15 (3) (2023)